Story no.231OngoingHealthNotableCôte-d'Or +128 Oct → 10 Nov18 facts · 70 art.
Anti-obesity in France: reimbursement, waiting times, and parallel market
In early November 2026, four and a half months after the start of reimbursement for Mounjaro and Wegovy, waiting times for a specialized consultation reach up to 18 months and a parallel market is developing. Patients in Dijon face strict BMI criteria and complex procedures, while a survey indicates that nearly one in five French people would be willing to take GLP-1s to lose weight. The appetite suppressant market is experiencing strong growth and adverse effects are multiplying, with customs stepping up controls against trafficking of products like Wegovy. On November 7, health risks linked to the diverted use of Ozempic and Wegovy are highlighted, and the 100 million euro envelope for reimbursement is deemed insufficient. In the following days, influencers are accused of diverting these medications, patients turn to parallel markets, and health professionals warn about harmful substances and side effects.
In brief
Ongoing story bringing together 18 events nationwide, followed from 28 October 2026 to 10 November 2026. 70 articles from 23 sources (health); last updated on 10 November 2026 at 11:05.
58 articles of rated outlets · 12 unrated outside the bar · 23 sources (70 art.) · the three sides talk about it · outlets: left 5, centre 15, right 2
Angle comparison for the whole story
All three sides cover the arrival of Wegovy in tablet form, but the left emphasizes industrial competition and reimbursement conditions, the center details waiting times, the parallel market, and patient testimonials, while the right highlights the non-reimbursable nature and practical information (price, side effects).
Left
Highlights the rivalry between Novo Nordisk and Eli Lilly on a rapidly growing global market, as well as the lack of reimbursement for the pills and the side effects to be aware of.
Centre
Details the concrete consequences: waiting times up to 18 months, parallel market, positioning of drug treatments versus bariatric surgery, and patient testimonials.
Right
Emphasizes the non-reimbursable nature of oral Wegovy and provides a practical format listing price, side effects, and reimbursement.
Written by an AI from headlines and extracts only of all events in the story · 2 Nov, 03h41
Confirmed by several sources(5)
- 7
Wegovy in tablet form is marketed in France starting November 2.
7 independent sourcesBFMTV / RMC, Paris-Normandie, Midi Libre, 20 Minutes, La Dépêche du Midi +4
- 5
Oral Wegovy is sold at the recommended price of 169 euros per month and is not reimbursed.
5 independent sourcesMidi Libre, Le Moniteur des pharmacies, 20 Minutes, Libération, Les Échos
- 2
Waiting times in specialized consultations authorized to prescribe anti-obesity drugs reach up to 18 months.
2 independent sourcesLes Échos, Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain
- 2
Oral Wegovy contains semaglutide, a GLP-1 receptor agonist.
2 independent sourcesParis-Normandie, TF1 Info / LCI
- 2
Injectable Wegovy has been available in France since 2024 and reimbursed under conditions since June 2026.
2 independent sourcesLe Progrès, TF1 Info / LCI
Single source so far(5)
- The European Commission authorized oral Wegovy on July 15, 2026. (according to Paris-Normandie)
- A parallel market for these drugs is thriving, difficult to quantify. (according to Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain)
- Professor Emmanuel Disse stated: “The more patients we treat, the more bariatric surgery there will be.” (according to Le Progrès, Le Bien Public, L'Est Républicain)
- Meta Tshiteya, treated with Mounjaro for three years, has lost 50 kg. (according to L'Est Républicain, Le Dauphiné libéré, Le Progrès)
AI cross-check of the headlines and extracts of 28 articles (18 outlets) · “confirmed” = reported by at least two independent outlets · 1 Nov, 22h41
Checked on the web(3)
- Not confirmed at this stage
Wegovy in tablet form is marketed in France starting November 2.
Sources: ansm.sante.fr(official), www2.assemblee-nationale.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr
1 Nov, 22h44
- Not confirmed at this stage
Oral Wegovy is sold at the recommended price of 169 euros per month and is not reimbursed.
Sources: ansm.sante.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr, prescrire.org
1 Nov, 22h44
- Not confirmed at this stage
The European Commission authorized oral Wegovy on July 15, 2026.
Sources: lagazettefrance.fr, prescrire.org, ameli.fr, qare.fr, 20minutes.fr
1 Nov, 22h44
Automatic web search, official sources first · “contradicted” only when an official source is cited
Timeline
newest firstOutlets:LeftCentreRightUncategorised· badge = severity
In figures
Further reading
People cited
Organisations cited
Places cited
Go up the thread
Events in the story
- Une campagne anti-grossophobie de Lilly France soupçonnée de publicité déguisée pour le Mounjaro10 Nov
- Les risques sanitaires des traitements anti-obésité Ozempic et Wegovy9 Nov
- Alerte des professionnels de santé sur des piqûres pour maigrir9 Nov
- Un ancien obèse alerte sur l'effet « dévastateur » du Wegovy sur M68 Nov
- Wegovy tablet arrives in French pharmacies8 Nov
- Près d'un Français sur cinq prêt à prendre des anti-obésité GLP-1 pour maigrir8 Nov
- Un nutritionniste fait le point sur les médicaments anti-obésité8 Nov
- Des Français prêts à contourner les prescriptions pour accéder aux anti-obésité8 Nov
- Des influenceuses détournent les médicaments anti-obésité pour vanter leur minceur8 Nov
- Remboursement de l'obésité : l'enveloppe de 100 millions jugée insuffisante7 Nov
Affected departments